Trials / Not Yet Recruiting
Not Yet RecruitingNCT06705725
Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 38 (estimated)
- Sponsor
- Carbiogene Therapeutics Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CBG002 CAR-T Cell Suspension | Single dose of CAR+ T cells will be infused, and classic "3+3" dose escalation will be applied. |
Timeline
- Start date
- 2024-12-26
- Primary completion
- 2027-10-25
- Completion
- 2028-02-22
- First posted
- 2024-11-26
- Last updated
- 2024-11-26
Source: ClinicalTrials.gov record NCT06705725. Inclusion in this directory is not an endorsement.